Dosing and administration for MENVEO
Implementing MENVEO into your practice
MENVEO can help protect your younger and older adolescent patients.
|MENVEO Dosing for Younger and Older Adolescents1|
|Primary Vaccination||Booster Vaccination|
|Single dose in adolescents and adults aged 11 through 55 years||Single booster dose may be administered to individuals 15 through 55 years of age who are at continued risk of meningococcal disease, at least 4 years after a prior dose of a MenACWY vaccine|
Consider MENVEO for your at-risk patients as young as 2 months of age
|MENVEO Dosing for Infants1|
|2 Months of Age||7 Months Through 23 Months of Age|
|4-dose series with a single dose (0.5 mL) at 2, 4, 6, and 12 months of age||2-dose series (0.5 mL each) with the second dose administered in the second year of life, at least 3 months after the first dose|
Reconstitution for MENVEO
PULL the entire contents of MenCYW-135 liquid (Vial 1) from the vial while slightly tilting.
MIX the MenCYW-135 liquid with the MenA conjugate (Vial 2).
INVERT the vial and shake well until powder is completely dissolved.
After reconstitution, withdraw 0.5 mL from the vial containing the reconstituted vaccine. Each dose of MENVEO should be administered as a single 0.5-mL intramuscular injection, preferably into the anterolateral aspect of the thigh in infants or into the deltoid muscle (upper arm) in toddlers, adolescents, and adults. Do not administer MENVEO intravenously, subcutaneously, or intradermally.
MenACWY=meningococcal serogroups A, C, W, Y.